SLC7A13: A Drug Target and Potential Biomarker for glutamate Transporter 1

Target Name: SLC7A13

NCBI ID: G157724

SLC7A13

SLC7A13: A Drug Target and Potential Biomarker for glutamate Transporter 1

Introduction

Sodium-independent aspartate/glutamate transporter 1 (SLC7A13) is a protein that plays a crucial role in the transport of aspartate and glutamate across cell membranes. It is a member of the SLC transporter family, which is known for its ability to transport a wide variety of molecules across cell membranes with varying levels of selectivity. SLC7A13 is unique in that it is sodium-independent, meaning that it can transport aspartate and glutamate without the need for an external sodium source.

SLC7A13 is expressed in many different tissues and cells throughout the body, including the brain, spinal cord, and peripheral nerves. It is involved in the regulation of synaptic neurotransmitter release, and has been implicated in a number of neurological and psychiatric disorders.

Drug Target Potential

SLC7A13 is a drug target of great interest due to its unique transport mechanism and its involvement in neurological disorders. Many of the neurotransmitters that are used to treat psychiatric and neurological disorders, such as antidepressants and anti-seizure drugs, transport through SLC7A13. Therefore, inhibiting SLC7A13 could potentially be a useful strategy for treating these disorders.

One of the challenges in targeting SLC7A13 is its widespread distribution across different tissues and cells. However, recent studies have identified potential drug targets within SLC7A13 that could be targeted with small molecules. For example, several studies have identified a putative binding site within the SLC7A13 protein that is within the region of the transporter that is involved in ligand binding. Additionally, studies have shown that SLC7A13 is involved in the regulation of neurotransmitter release, and that inhibiting this regulation could be a potential drug target.

Biomarker Potential

SLC7A13 is also a potential biomarker for a number of neurological disorders. The regulation of neurotransmitter release by SLC7A13 is disrupted in a number of psychiatric and neurological disorders, such as depression, anxiety, and epilepsy. Therefore, SLC7A13 has the potential to serve as a biomarker for these disorders.

Importance of SLC7A13 as a drug target and biomarker

SLC7A13 is a protein that plays a crucial role in the regulation of neurotransmitter release and has been implicated in a number of neurological and psychiatric disorders. The unique transport mechanism of SLC7A13, which is sodium-independent, makes it an attractive target for small molecules. Furthermore, SLC7A13 is involved in the regulation of neurotransmitter release and has been implicated in a number of psychiatric and neurological disorders, making it a potential biomarker for these disorders.

Conclusion

Sodium-independent aspartate/glutamate transporter 1 (SLC7A13) is a protein that plays a crucial role in the transport of aspartate and glutamate across cell membranes. Its unique transport mechanism and its involvement in the regulation of synaptic neurotransmitter release make it an attractive target for small molecules. Furthermore, SLC7A13 is involved in the regulation of neurotransmitter release and has been implicated in a number of psychiatric and neurological disorders, making it a potential biomarker for these disorders. Further research is needed to fully understand the role of SLC7A13 in neurotransmission and to develop effective treatments for psychiatric and neurological disorders.

Protein Name: Solute Carrier Family 7 Member 13

Functions: Mediates the transport L-aspartate and L-glutamate in a sodium-independent manner

The "SLC7A13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets